文献速递浆细胞疾病

载脂蛋白A1对多发性骨髓瘤预后的影响

[The influence of apolipoprotein A1 on the prognosis of multiple myeloma].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2020-01-01

该研究纳入412例多发性骨髓瘤患者与93名健康对照,分析血清载脂蛋白A1水平变化及其临床意义。骨髓瘤组Apo A1低于对照组(0.89 g/L对1.24 g/L,P<0.05),且随疾病阶段动态变化;Apo A1降低是多发性骨髓瘤的独立危险因素,高Apo A1组有更高的生存率和更长的无进展生存期。

要点

  • 骨髓瘤患者血清Apo A1水平低于健康对照(0.89 g/L对1.24 g/L,P<0.05)。
  • Apo A1随疾病阶段动态变化:缓解时升高,进展时降低。
  • Apo A1降低是多发性骨髓瘤的独立危险因素,高Apo A1组OS和PFS更长。

核心结论

  • 载脂蛋白A1是多发性骨髓瘤有效的肿瘤负荷标志物和预后因素。

研究设计与样本

  • 回顾性分析412例多发性骨髓瘤患者临床资料,以93名健康体检者为正常对照。
  • 使用SPSS 22.0进行数据分析,相关分析采用线性相关或Spearman秩相关系数。
  • 组间比较采用t检验、Mann-Whitney U检验或单因素方差分析,采用ROC曲线计算分界值,Kaplan-Meier生存分析比较高低Apo A1组OS和PFS。

主要发现

  • 骨髓瘤组Apo A1水平低于正常对照组(0.89 g/L对1.24 g/L,P<0.05)。
  • Apo A1水平随疾病不同阶段动态变化,疾病缓解时升高,疾病进展时降低。
  • 多因素分析表明Apo A1减少是多发性骨髓瘤的独立危险因素。
  • 高Apo A1组与低Apo A1组的Kaplan-Meier生存分析显示高Apo A1组有更高的生存率和更长的无进展生存期。

关键数值与推荐

  • 骨髓瘤组与对照组Apo A1比较:0.89 g/L对1.24 g/L,P<0.05。
  • 采用ROC曲线计算Apo A1分界值,据此分为高Apo A1亚组与低Apo A1亚组。

临床怎么用

  • 可将血清Apo A1作为评估多发性骨髓瘤肿瘤负荷和预后的生物标志物。
  • 动态监测Apo A1水平有助于判断疾病缓解或进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: In this study, we aimed to determine the change and clinical significance of serum level Apo A1 in MM patients. Methods: In total, 412 multiple myeloma patients were examined. SPSS 22.0 was used for data analysis. Correlation analysis was performed using linear correlation or Spearman rank correlation coefficients. Measurement data were analyzed with the t-test, Mann-Whitney U-test, or oneway analysis of variance (ANOVA) . Used the ROC curve to calculate the cutoff value and compared the OS and PFS between high Apo A1 subgroup and low Apo A1 subgroup with Kaplan-Meier survival analysis. Results: Our study showed that value of Apo A1 in the patient group was lower than that in the control group (0.89 g/L vs 1.24 g/L, P<0.05) . We found that Apo A1 dynamically changed with different MM stages. As it was increased when the disease was in remission, and decreased after disease in progression. According the result of multivariate analysis Apo A1 reduction become the independent risk factors of MM. On the basis of Kaplan-Meier survival analysis between high Apo A1 subgroup and low Apo A1 subgroup, we found higher Apo A1 patienta had longer OS rate and PFS. Conclusions: Apo A1 is a useful biomarker of tumor burden and a prognostic factor of multiple myeloma. 目的: 探讨多发性骨髓瘤患者血清载脂蛋白A1水平的变化及其临床意义。 方法: 统计412例多发性骨髓瘤患者的临床资料,以93名健康体检者为正常对照,使用SPSS 22.0进行数据分析。相关分析采用线性相关或Spearman秩相关系数。分析数据采用t检验、Mann-Whitney U检验或单因素方差分析。采用ROC曲线计算分界值,并与Kaplan-Meier生存分析进行比较。 结果: 骨髓瘤组载脂蛋白A1水平低于正常对照组(0.89 g/L对1.24 g/L,P<0.05)。载脂蛋白A1水平随疾病的不同阶段动态变化,当疾病缓解时载脂蛋白A1水平可升高,疾病进展时载脂蛋白A1水平降低。多因素分析表明载脂蛋白A1减少是多发性骨髓瘤的独立危险因素。高载脂蛋白A1组与低载脂蛋白A1组的Kaplan-Meier生存分析显示高载脂蛋白A1组有更高的生存率和更长的无进展生存期。 结论: 载脂蛋白A1是多发性骨髓瘤有效的肿瘤负荷标志物和预后因素。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Shen J, Yang RH, Zhang YC, et al. [The influence of apolipoprotein A1 on the prognosis of multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 32942823. doi:10.3760/cma.j.issn.0253-2727.2020.08.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。